TD Cowen sets USD 3.00 target for Geron stock

Published on 10/27/2026 at 20:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Geron reports USD 57.48 million revenue for the second quarter of 2026. Geron stock costs EUR 1.03 on October 27, 2026 at 8:02 p.m. CEST.

Analyst target and reporting date

TD Cowen analyst Tara Bancroft set a USD 3.00 target on October 22, 2026.
Second-quarter 2026 revenue was USD 57.48 million versus USD 49.04 million in the prior-year quarter.
Geron stock costs EUR 1.03 at Lang & Schwarz on October 27, 2026 at 8:02 p.m. CEST.
Geron will release third-quarter 2026 results on November 4, 2026.

GERN, US3741631036, Illustration mit AI erstellt.

TD Cowen analyst Tara Bancroft maintained a Buy rating on Geron and set a USD 3.00 price target on October 22, 2026, as Markets Insider reported. Geron stock was trading at EUR 1.03 at Lang & Schwarz on October 27, 2026 at 8:02 p.m. CEST.

Revenue gives the next test

Geron's second-quarter 2026 revenue reached USD 57.48 million, compared with USD 49.04 million in the second quarter of 2025. The GAAP net loss was USD 16.68 million, versus USD 16.38 million a year earlier, according to Benzinga.

The commercial picture rests on RYTELO, Geron's approved treatment for certain patients with lower-risk myelodysplastic syndromes. Management said second-quarter demand grew 5.00 percent from the first quarter and prescribing accounts reached 1,575 since launch, while full-year 2026 RYTELO net product revenue guidance stood at USD 220 million to USD 240 million.

Stock frame stays wide

On the Nasdaq, Geron last traded at USD 1.15 on October 27, 2026 at 3:03 p.m. EDT. The same session showed 4,239,330 shares in volume, a market capitalization of USD 735.6 million and a 52-week range of USD 1.04 to USD 2.01. The Nasdaq quote places the stock 10.58 percent above its yearly low and 42.79 percent below its yearly high.

November brings the next date

Geron announced on October 21, 2026 that it will publish third-quarter 2026 financial results before the market opens on November 4, 2026, followed by an 8:00 a.m. EDT conference call, according to the Geron release. The release date gives investors the next scheduled checkpoint for RYTELO sales, operating expenses and clinical progress.

Cash supports commercial execution

Geron reported USD 327.0 million in cash, cash equivalents, restricted cash and marketable securities at June 30, 2026. That liquidity sits alongside a quarterly loss and makes the November report important for judging how sales growth is translating into cash use.

Geron stock at EUR 1.03

At Lang & Schwarz, Geron stock was trading at EUR 1.03 on October 27, 2026 at 8:02 p.m. CEST. On the Nasdaq, the stock last traded at USD 1.15 on October 27, 2026 at 3:03 p.m. EDT. The further course of trading is shown by the continuously updated real-time quote of Geron stock.